Grant winners to investigate continuous manufacturing for gene therapies
Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.
Cobra Biologics has won a £1.5 million shared grant from Innovate UK, the UK’s innovation agency. Co-winners, Pall Corporation, a global leader in filtration, separation and purification, and the Cell and Gene Therapy Catapult, an independent research and technology organization focused on advancing the growth of the UK cell and gene therapy industry, will work with Cobra Biologics to investigate continuous manufacturing of adeno-associated virus (AAV) for gene therapy applications.
“In light of the unprecedented clinical successes with a number of advanced therapy medicinal products, we are looking forward to working with Pall and the Cell and Gene Therapy Catapult. Together we will innovative in-process analytical techniques and manufacturing approaches based on continuous chromatography platforms, to significantly increase process yields, and, in doing so, make these advanced therapies more accessible to patients,” said Peter Coleman, CEO of Cobra Biologics.
“Yields for downstream processing of AAV are currently very low and the production process is costly in both time and consumables,” explained Mario Philips, Vice President & General Manager of Pall Biotech. “With this project, we hope to advance the AAV purification process and affect a 25% or more step change in purification yields. The Pall Cadence BioSMB system will be investigated for its ability to increase yields and decrease cost, while using novel analytical procedures to enhance the purification process.”
“Our shared vision is to take a major step towards continuous processing for gene therapy production. We each bring strengths and a unique perspective to this collaborative R&D project,” added Keith Thompson, CEO of the Cell and Gene Therapy Catapult. “As we move forward, we will create a scalable continuous process that increases efficiencies in time and cost, to make commercialization of gene therapies safer, faster, and cheaper than ever before. We are excited to play a key role in increasing patient access to these potentially life-changing therapies and to further establish best practices in manufacturing.”
The transition from batch to continuous chromatography will be planned and managed by all parties. The project began in September 2018.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance